email article The FDA accepted Avadel Pharmaceuticals' marketing application for a daily sodium oxybate treatment, FT218, for excessive daytime sleepiness and cataplexy in adults with narcolepsy, the company said. England saw a nearly 4% uptick in new antidepressant prescriptions during the COVID-19 pandemic. ( The Lancet Psychiatry) Diversity, equity, and inclusion leaders in academic medicine often don't have the resources they need to implement change, according to a new "guideline for success" in the American Journal of Psychiatry. Luvadaxistat, an investigational treatment for negative symptoms of schizophrenia, failed in a phase II trial. ( BioPharmaDive) But in other trial news, an accelerated 5-day course of intermittent theta-burst stimulation with Nexstim's Navigated Brain Therapy device succeeded in reducing symptoms of severe depression, the maker announced.